Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Is the Forecast for the Antispasmodics Drugs Market from 2024 to 2025?

In recent years, the market size of antispasmodics drugs has seen significant growth. Projected to expand from $13.76 billion in 2024 to $15.07 billion in 2025, it has a compound annual growth rate (CAGR) of 9.5%. The growth witnessed in the historical period is attributed to factors such as increased occurrence of spasmodic conditions, advancements in medical research, growing elderly population, shifting lifestyles, and improvements in diagnosis capabilities.

What Is the Projected Market Size of the Antispasmodics Drugs Market?

Expectations are high for the antispasmodics drugs market, as strong growth is projected over the next several years. The market is set to attain a value of $21.91 billion by 2029, moving forward at a compound annual growth rate (CAGR) of 9.8%. Observers link this predicted growth during the forecast period to several factors such as increased spending on healthcare, the rise of personalized medicine, worldwide population growth, expansion in emerging markets, and advancements in clinical trials and research. In the forecast period, key trends to look out for include the broadening of applications for antispasmodics, development in healthcare infrastructure, progress in drug development, heightened awareness and diagnosis, and a growing preference for non-invasive treatment alternatives.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=9414&type=smp

Who are the Major Competitors in the Antispasmodics Drugs Market Outlook?

Major companies operating in the antispasmodics drugs market include Daiichi Sankyo Company Limited, Fresenius Kabi AG, Hikma Pharmaceuticals plc, Johnson & Johnson Services Inc., Pfizer Inc., Shanghai Fosun Pharmaceutical Co. Ltd., Takeda Pharmaceutical Company Limited, Akorn Inc., Aurobindo Pharma Limited, Lannett Company Inc., Nexus Pharmaceuticals Inc., Actiza Pharmaceutical Private Limited, Blue Cross Laboratories Pvt. Ltd., Dr. Reddy’s Laboratories Ltd., Lexicare Pharma Pvt. Ltd., Solitaire Pharmacia Private Limited, Strides Pharma Science Limited, Wellona Pharma Private Limited, SunGen Pharma LLC, GlaxoSmithKline plc, Novartis AG, Sanofi SA, AstraZeneca plc, Merck & Co. Inc., Bayer AG, Teva Pharmaceutical Industries Ltd., Endo Pharmaceuticals Inc., Sun Pharmaceutical Industries Ltd., Cipla Ltd., Lupin Ltd.

What Is Fueling Growth in the Antispasmodics Drugs Market?

The anticipated rise in the senior population is projected to stimulate the expansion of the antispasmodic drug market. Individuals aged 65 and above, who are categorized as senior citizens, grapple with a collection of physical and mental health problems. Antispasmodic medications offer relief to this population group by controlling symptoms linked to various conditions which may result in muscle spasms or pain. These medications can also be used to manage conditions such as irritable bowel syndrome (IBS), gastroesophageal reflux disease (GERD), interstitial cystitis, and uterine cramps. For instance, the World Health Organization (WHO), a Switzerland-based international public health entity, forecasted in October 2022 that the global ratio of individuals aged 60 and above will escalate to 1.4 billion by 2030. The world’s count of people aged 60 and beyond is expected to double by 2050, reaching 2.1 billion. The population of those 80 years and older is also set to significantly rise, hitting 426 million by 2050. Consequently, the surging elderly population will fuel the growth of the antispasmodic drug market.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=9414&type=smp

Which Antispasmodics Drugs Market Segments Are Growing the Fastest?

The antispasmodics drugs market covered in this report is segmented –

1) By Drug: Dicyclomine Hydrochloride, Loperamide Hydrochloride, Other Drugs

2) By Indication: Irritable Bowel Syndrome, Stomach Cramps, Other Indications

3) By Route Of Administration: Oral, Parenteral, Other Modes Of Administrations

4) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy

5) By End-User: Hospitals, Homecare, Specialty Clinics, Other End-Users

Subsegments:

1) By Dicyclomine Hydrochloride: Oral Tablets, Injectable Formulations

2) By Loperamide Hydrochloride: Oral Tablets, Liquid Formulations

3) By Other Drugs: Hyoscine Butylbromide (Scopolamine), Peppermint Oil, Atropine, Other Antispasmodics

Which Industry Trends Are Shaping the Future of the Antispasmodics Drugs Market?

The emergence of product novelties is a prominent trend garnering acclaim within the antispasmodic drugs industry. Principal businesses in the antispasmodic drugs trade are concentrating on the creation of revolutionary solutions to fortify their market standing. To illustrate, Ardelyx Inc., an American biopharmaceutical company, announced in April 2022 the launch of IBSRELA, a unique NHE-3 inhibitor designed to assist those suffering from irritable bowel syndrome with constipation (IBS-C). As substantiated in Phase 3 clinical research, this product is a distinct new therapeutic alternative that utilizes a novel mode of operation to produce substantial and effective results in treating constipation and several abdominal symptoms typically experienced by IBS-C patients.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/antispasmodics-drugs-global-market-report

Which Countries Are Leading the Antispasmodics Drugs Market?

North America was the largest region in the antispasmodics drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the antispasmodics drugs market report during the forecast period. The regions covered in the antispasmodics drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=9414

This Report Delivers Insight On:

1. How big is the antispasmodics drugs market, and how is it changing globally?

2. Who are the major companies in the antispasmodics drugs market, and how are they performing?

3. What are the key opportunities and risks in the antispasmodics drugs market right now?

4. Which products or customer segments are growing the most in the antispasmodics drugs market?

5. What factors are helping or slowing down the growth of the antispasmodics drugs market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 2071930708

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model